Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received December 15, 2008
- Accepted February 2, 2009
- Published online May 13, 2009.
Copyright & Usage
Copyright© 2009 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved
Author Information
- JEROME H. CHECK,
- EBONY DIX,
- LYNN SANSOUCIE and
- DIANE CHECK
- Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, The University of Medicine and Dentistry of New Jersey, Medical Wood Johnson Medical School at Camden, Cooper Hospital/University Medical Center, Camden, NJ, U.S.A.
- Correspondence to: Jerome H. Check, MD, Ph.D., 7447 Old York Road, Melrose Park, PA 19027, U.S.A. Tel: +215 6354156, Fax: +215 6352304, e-mail: laurie{at}ccivf.com
Statistics from Altmetric.com
Cited By...
In this issue
Jump to section
Related Articles
Cited By...
- Lung Cancer - Standard Therapy and the Use of a Novel, Highly Effective, Well Tolerated, Treatment With Progesterone Receptor Modulators
- New Insights as to Why Progesterone Receptor Modulators, such as Mifepristone, Seem to Be More Effective in Treating Cancers that Are Devoid of the Classical Nuclear Progesterone Receptor
- Palliative Benefits of Oral Mifepristone for the Treatment of Metastatic Fibroblastic Osteosarcoma
- Treatment With Mifepristone Allows a Patient With End-stage Pancreatic Cancer in Hospice on a Morphine Drip to Restore a Decent Quality of Life
- Therapy Aimed to Suppress the Production of the Immunosuppressive Protein Progesterone Induced Blocking Factor (PIBF) May Provide Palliation and/or Increased Longevity for Patients With a Variety of Different Advanced Cancers - A Review
- Mifepristone Extends Both Length and Quality of Life in a Patient With Advanced Non-small Cell Lung Cancer that Has Progressed Despite Chemotherapy and a Check-point Inhibitor
- Long-term High-quality Survival with Single-agent Mifepristone Treatment Despite Advanced Cancer
- Mifepristone Causing Complete Remission of Rapidly Advancing Leukemia with Measurement of Progesterone-induced Blocking Factor
- Evidence that Mifepristone, a Progesterone Receptor Antagonist, Can Cross the Blood Brain Barrier and Provide Palliative Benefits for Glioblastoma Multiforme Grade IV
- Progesterone Receptor Antagonist Therapy Has Therapeutic Potential Even in Cancer Restricted to Males as Evidenced from Murine Testicular and Prostate Cancer Studies
- Efficacy of the Progesterone Receptor Antagonist Mifepristone for Palliative Therapy of Patients with a Variety of Advanced Cancer Types